It will be a juggernaut, once cleared at FDA -- bank on that. This is a high burden disease.
Yep, efinopegdutide has been shown to be highly effective -- in combatting MASH. Here's the latest, from the scientific journals and confabs (The Lancet, included):
. . .[Merck] today announced the presentation of positive results from the company’s Phase 2b clinical trial that evaluated the safety and efficacy of three doses of once-weekly, subcutaneous efinopegdutide (4 mg, 7 mg and 10 mg), an investigational injectable GLP-1/glucagon receptor co-agonist, versus placebo for the treatment of adults with MASH and stage F2 or F3 liver fibrosis. The findings were presented during a late-breaking abstract session at The Liver Meeting (TLM), being held in Denver, Colo., and simultaneously published in The Lancet. . . .
“MASH poses a substantial risk of progression to cirrhosis and ultimately liver failure, underscoring the urgent need for new treatment options,” said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. “We are highly encouraged by these results which add to the evidence that efinopegdutide, a distinct GLP-1/glucagon receptor co-agonist, has the potential to provide clinically meaningful responses for MASH resolution and fibrosis regression. . . .”
True, this wonder drug is not on-market, yet -- anywhere -- but it will be, given the above results. Good work, you Merckies!
नमस्ते



































